SEC Form 4 · accession 0001209191-19-014255
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Louise Collins
Officer — SVP and Chief Medical Officer
Period of report
Feb 25, 2019
Accepted (ET)
Feb 27, 2019 · 7:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 25, 2019 | A | 10,000 | $0.00 | A | 40,971 | D | |
| Common Stock | Feb 26, 2019 | F | 1,177 | $11.95 | D | 39,794 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $11.97 | Feb 25, 2019 | A | 58,000 | A | — | Feb 24, 2029 | Common Stock | 58,000 | 58,000 | D |
Explanation of responses
- F1Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 25, 2020, 2021 and 2022, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date.
- F2The shares underlying the option vest at a rate of one forty-eighth (1/48) per month following February 25, 2019, provided the reporting person provides services to the Company through each such date.